Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? (Q47732726)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

main subject

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author

Marina Elena Cazzaniga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

L Cortesi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A Ferzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

L Scaltriti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

F Cicchiello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M Ciccarese

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

S Della Torre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

F Villa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M Giordano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

C Verusio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M Nicolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A R Gambaro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

L Zanlorenzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

E Biraghi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

E Casini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

L Legramandi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

3 December 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Breast Cancer

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

1683060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

9 April 2020

start time

1 January 2017

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Metronomic chemotherapy for triple negative breast cancer?

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5733132

14 August 2018

Identifiers

DOI

10.1155/2017/1683060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

PubMed publication ID

29333297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29333297%20AND%20SRC:MED&resulttype=core&format=json